TD Cowen Downgrades ADC Therapeutics to Market Perform
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Boris Peaker has downgraded ADC Therapeutics (NYSE:ADCT) from Outperform to Market Perform.

November 09, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ADC Therapeutics has been downgraded by TD Cowen from Outperform to Market Perform.
Analyst ratings often have a significant impact on a company's stock price. A downgrade from Outperform to Market Perform suggests that the analyst believes the company's stock will perform similarly to other stocks in the market, rather than outperforming them. This could lead to a decrease in investor interest and potentially a drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100